Estimation of radiation doses for atomic-bomb survivors in the Hiroshima University Registry
- Hiroshima Univ., Kasumi (Japan)
- Hiroshima A-bomb Casualty Council Health Management Promotion Center, Senda-machi Naka-ku (Japan)
The present study presents the Hiroshima University Registry of atomic bomb survivors, of which the total number is about 270,000, and application of absorbed doses. From this registry, we picked up 49,102 survivors and applied organ doses based on the dosimetry system 1986 (DS86), which is named the Atomic Bomb Survivor 1993 Dose (ABS93D). The applied dose data are based on the tables listed in the DS86 final report such as the free-in-air kermas, the house shielding factors, and organ dose factors for the active bone marrow and the breast. Calculations for the 13 other organs provided in DS86 are possible. To obtained the organ doses for each survivor, it is necessary to obtain information concerning (1) place exposed, (2) whether they were shielded or not, and (3) age. ABS93D body transmission factors for active bone marrow for neutrons and gamma rays agreed with DS 86 to within a few percent. Of the survivors studied, 35, 123 of them were used for the relative risk estimation of leukemia mortality, adopting the same method as the Radiation Effects Research Foundation (RERF) for comparison. For the observation period from 1968 to 1989, the analyzed relative risks for leukemia mortality at 1 Gy by shielded kerm and by active bone marrow dose are 2.01 and 2.37, respectively, which are consistent with the RERF results. 11 refs., 1 fig., 3 tabs.
- Sponsoring Organization:
- USDOE
- OSTI ID:
- 283167
- Journal Information:
- Health Physics, Vol. 70, Issue 5; Other Information: PBD: May 1996
- Country of Publication:
- United States
- Language:
- English
Similar Records
Cancer incidence in atomic bomb survivors. Part I: Use of the tumor registries in Hiroshima and Nagasaki for incidence studies
Studies of the mortality of A-bomb survivors. 9. Mortality, 1950-1985: Part 1. Comparison of risk coefficients for site-specific cancer mortality based on the DS86 and T65DR shielded kerma and organ doses